In this commentary, we analyze the findings of Cao et al. (2025) (1) and their implications for redefining metabolic risk assessment in non-obese adults. We focus on the Atherogenic Index of Plasma (AIP) as a valuable predictive tool for metabolic risk, its clinical applicability, and the critical need for further research to address current gaps in knowledge. The study highlights a crucial aspect of metabolic health—the risk of type 2 diabetes mellitus (T2DM) in individuals who, despite not meeting the BMI criteria for obesity, may still present with elevated metabolic risk factors.Expanding the Role of AIP in People Without ObesityBody Mass Index (BMI) is commonly used to evaluate metabolic risk, but it is clear that BMI alone does not capture the full picture. Many individuals classified as underweight or normal weight still develop metabolic disorders, suggesting the need for additional markers. Although the present commentary focuses on non-obese individuals, it is essential to acknowledge that AIP has also demonstrated strong associations with metabolic dysfunction in overweight and obese populations. Li et al. (2024), in a cohort of over 40,000 Chinese adults with elevated BMI, reported a J-shaped relationship between AIP and type 2 diabetes, with inflammatory mediators such as neutrophils and monocytes partially explaining the observed risk gradient (2). Complementarily, Karimpour Reyhan et al. (2024) identified AIP as the most accurate lipid index for detecting overweight and obesity in patients with T2DM, outperforming conventional lipid ratios with an AUC of 0.770 (3). These findings underscore the broader applicability of AIP as a biomarker of cardiometabolic risk, irrespective of adiposity status. Large-scale studies have further demonstrated that AIP is a strong predictor of metabolic risk even in non-obese individuals. Huang et al. (2024) analyzed data from over 85,000 normoglycemic adults with BMI <25 kg/m² and found a significant non-linear association between the TG/HDL-C ratio—a surrogate for AIP—and incident diabetes, with an inflection point at 1.36 (4). Similarly, Wu et al. (2022) reported a robust association between AIP and prediabetes in non-obese individuals with normal LDL-C levels, identifying a clinically relevant threshold at 1.617 (5). These findings support broader evidence indicating a non-linear relationship between AIP and diabetes risk, suggesting that even in the absence of obesity, elevated AIP levels may strongly predict increased predisposition to developing T2DM(1). However, the exact physiological mechanisms underlying this association remain to be fully elucidated. Given that AIP primarily reflects the triglyceride-to-HDL-C ratio, it is likely that chronic dyslipidemia, low-grade inflammation, and insulin resistance contribute to the observed link with diabetes (6, 7). Further exploration of these pathways is necessary to determine whether AIP is simply a surrogate marker or an independent metabolic risk factor. A recent cohort study further supports this association, demonstrating that higher AIP levels predict long-term diabetes risk even among individuals with normal fasting plasma glucose(8). The new consensus published by The Lancet Diabetes & Endocrinology (2025) advocates for a shift away from BMI-centric definitions of obesity, emphasizing metabolic dysfunction as a key diagnostic criterion (9). Despite this growing consensus, there remains significant debate on the best markers to replace BMI in clinical practice. Some researchers argue that waist-to-hip ratio, visceral fat quantification, and insulin resistance indices may offer more robust predictive value than AIP alone (10, 11). Comparative studies between these markers and AIP would be valuable to determine the optimal screening approach.Clinical Implications and Integration into PracticeCao et al. (2025) (1) identified a non-linear association between AIP and diabetes risk, with a threshold at AIP = -0.268. Individuals with AIP values above this point had a significantly higher risk of developing diabetes (HR 1.763, 95% CI: 1.210-2.568, p = 0.003) (1). This suggests the potential value of incorporating AIP into standard blood test panels and combining it with established tools such as the Framingham Risk Score. A summary comparison of AIP and traditional lipid markers is presented in Table 1.Compared to traditional lipid markers like LDL-C, HDL-C, and triglycerides, AIP integrates the ratio between triglycerides and HDL-C, potentially offering more nuanced insight into lipid-driven metabolic risk (12). Although its predictive potential is promising, several limitations must be addressed before clinical adoption. One key concern is the lack of standardization in AIP cut-off values across different populations (13). Given that lipid profiles vary by ethnicity, dietary habits, and genetic background, a one-size-fits-all approach may not be appropriate (14, 15). Furthermore, the stability of AIP over time has not been well characterized—fluctuations in triglyceride and HDL-C levels due to acute illness, dietary changes, or medication use could impact AIP’s reliability. AIP has also been linked to insulin resistance and beta-cell dysfunction, two key mechanisms in T2DM development (12, 16). This supports the notion that AIP is more than just a lipid ratio; it may reflect deeper metabolic disturbances related to lipid metabolism and inflammation. However, its added predictive value over existing risk models such as HOMA-IR (17) or the triglyceride-glucose index (18) remains unclear. Large-scale comparative studies are needed to determine whether AIP offers a distinct advantage or simply mirrors existing markers. Current evidence suggests that AIP is directly associated with prediabetes development, although the relationship appears to be non-linear. Zheng et al. (2023) found that AIP values ≤ 0.03 were significantly associated with...